Ingenol Mebutate Approved for Topical Actinic Keratosis Therapy

Get Permission

FDAlogoThe FDA has approved ingenol mebutate (Picato) gel for the topical treatment of actinic keratosis. At a concentration of 0.015%, the gel is used once daily on the face and scalp for 3 consecutive days, whereas a 0.05% dosage form is used once daily on the trunk and extremities for 2 consecutive days. Ingenol mebutate gel is the first topical actinic keratosis therapy that can be used for as little as 2 or 3 days.

Studies show that about 65% of squamous cell carcinomas begin as untreated actinic keratosis, and guidelines from the American Academy of Dermatology estimate that 60% of predisposed persons older than 40 have at least one actinic keratosis.

In four phase III studies of more than 1,000 patients, a significantly higher proportion of those treated with ingenol mebutate gel (n = 503) saw complete clearance of actinic keratoses in the field of treatment, compared to placebo. ■




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.